Education
About Us
Working with TipRanks
Follow Us
Nuo Therapeutics (AURX)
OTHER OTC:AURX
Total Valuation
Nuo Therapeutics has a market cap or net worth of $105.80M. The enterprise value is ―.
Market Cap$105.80M
Enterprise Value―
Share Statistics
Nuo Therapeutics has 48,077,744 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,077,744
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Nuo Therapeutics’s return on equity (ROE) is -4.52 and return on invested capital (ROIC) is -362.56%.
Return on Equity (ROE)-4.52
Return on Assets (ROA)-1.95
Return on Invested Capital (ROIC)-362.56%
Return on Capital Employed (ROCE)-4.02
Revenue Per Employee151.69K
Profits Per Employee-258.19K
Employee Count9
Asset Turnover1.15
Inventory Turnover2.01
Valuation Ratios
The current PE Ratio of Nuo Therapeutics is ―. Nuo Therapeutics’s PEG ratio is 0.85.
PE Ratio―
PS Ratio46.58
PB Ratio123.79
Price to Fair Value123.79
Price to FCF-26.65
Price to Operating Cash Flow-117.21
PEG Ratio0.85
Income Statement
In the last 12 months, Nuo Therapeutics had revenue of 1.37M and earned -2.32M in profits. Earnings per share was -0.05.
Revenue1.37M
Gross Profit1.06M
Operating Income-2.46M
Pretax Income-2.32M
Net Income-2.32M
EBITDA-2.36M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -932.86K and capital expenditures -231.55K, giving a free cash flow of -1.16M billion.
Operating Cash Flow-932.86K
Free Cash Flow-1.16M
Free Cash Flow per Share-0.02
Dividends & Yields
Nuo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.06
52-Week Price Change62.59%
50-Day Moving Average2.33
200-Day Moving Average1.73
Relative Strength Index (RSI)50.13
Average Volume (3m)2.99K
Important Dates
Nuo Therapeutics upcoming earnings date is Aug 8, 2022, TBA (Confirmed).
Last Earnings DateMay 16, 2022
Next Earnings DateAug 8, 2022
Ex-Dividend Date―
Financial Position
Nuo Therapeutics as a current ratio of 1.45, with Debt / Equity ratio of -27.33%
Current Ratio1.45
Quick Ratio1.19
Debt to Market Cap0.00
Net Debt to EBITDA0.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nuo Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nuo Therapeutics EV to EBITDA ratio is -26.88, with an EV/FCF ratio of -26.60.
EV to Sales46.50
EV to EBITDA-26.88
EV to Free Cash Flow-26.60
EV to Operating Cash Flow-28.44
Balance Sheet
Nuo Therapeutics has $514.80K in cash and marketable securities with $114.69K in debt, giving a net cash position of $400.11K billion.
Cash & Marketable Securities$514.80K
Total Debt$114.69K
Net Cash$400.11K
Net Cash Per Share<$0.01
Tangible Book Value Per Share$0.01
Margins
Gross margin is 70.38%, with operating margin of -180.04%, and net profit margin of -170.21%.
Gross Margin70.38%
Operating Margin-180.04%
Pretax Margin-170.21%
Net Profit Margin-170.21%
EBITDA Margin-172.99%
EBIT Margin-180.04%
Analyst Forecast
The average price target for Nuo Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―